These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 3878574)

  • 1. Serum levels of prostatic acid phosphatase (PAP), tissue polypeptide antigen (TPA), CA-50, neopterine and of osteocalcin in patients with prostatic carcinoma.
    Lewenhaupt A; Ekman P; Eneroth P; Eriksson A; Nordström L
    Scand J Clin Lab Invest Suppl; 1985; 179():75-80. PubMed ID: 3878574
    [No Abstract]   [Full Text] [Related]  

  • 2. On reference values for tumor markers in prostatic carcinoma.
    Lewenhaupt A; Ekman P; Eneroth P; Kallner A
    Scand J Urol Nephrol Suppl; 1988; 110():119-23. PubMed ID: 3263693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostatic acid phosphatase and prostate-specific antigen in prostate cancer.
    Kuriyama M; Loor R; Wang MC; Lee C; Killian CS; Papsidero LD; Inaji H; Nishiura T; Slack NH; Murphy GP; Chu TM
    Int Adv Surg Oncol; 1982; 5():29-49. PubMed ID: 6178696
    [No Abstract]   [Full Text] [Related]  

  • 4. [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma].
    Yamazaki K; Kumamoto Y; Tsukamoto T; Umehara T; Ohmura K
    Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue polypeptide antigen (TPA) and prostatic acid phosphatase in serum of prostatic cancer patients.
    Huber PR; Rist M; Hering F; Biedermann C; Rutishauser G
    Urol Res; 1983; 11(5):223-6. PubMed ID: 6659214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspects on reference values for tumor markers in human prostatic carcinoma.
    Ekman P; Lewenhaupt A; Eneroth P; Kallner A
    Am J Clin Oncol; 1988; 11 Suppl 2():S80-2. PubMed ID: 2468281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific acid phosphatase versus five other possible tumour markers: a comparative study in men with prostatic carcinoma.
    Larson A; Fritjofsson A; Norlén BJ; Gronowitz JS; Ronquist G
    Scand J Clin Lab Invest Suppl; 1985; 179():81-8. PubMed ID: 2417306
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
    Marczyńska A; Kulpa J; Leńko J; Augustyn M
    Int Urol Nephrol; 1988; 20(2):123-9. PubMed ID: 2454895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic markers and the diagnosis of prostatic cancer.
    Ban Y; Wang MC; Chu TM
    Urol Clin North Am; 1984 May; 11(2):269-76. PubMed ID: 6203206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What is the use of the radioimmunoassay of prostatic acid phosphatase?].
    Luckacs B; Cohen L; Coloby P; Gattegno B; Michel F; Agnes E; Roland J; Thibault P
    J Urol (Paris); 1985; 91(4):211-4. PubMed ID: 2410516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the serum concentration of prostate-specific antigen as a biological marker in the evolution of disseminated prostatic cancer].
    Morote Robles J; de Torres Mateos JA; Soler-Roselló A
    Actas Urol Esp; 1988; 12(2):152-7. PubMed ID: 2458015
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
    Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
    J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tissue polypeptide antigen as a marker for prostatic neoplasms. Preliminary study].
    Ruibal A; Durán P; Ibarz L; Fraile M; Roca I; de Torres Mateos JA
    Arch Esp Urol; 1984; 37(5):399-403. PubMed ID: 6517625
    [No Abstract]   [Full Text] [Related]  

  • 15. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
    Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
    J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New prospective diagnostic serum markers in prostatic cancer].
    Mirone V; De Bellis G; Prezioso D; Sanseverino R; Iannucci F; Padulano P
    Minerva Med; 1986 Mar; 77(13):503-4. PubMed ID: 2422605
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tumor marker in urology].
    Shimazaki J; Ito H; Miyauchi T; Maruoka M; Isaka S; Masukagami T; Ando K
    Gan No Rinsho; 1983 May; 29(6):684-92. PubMed ID: 6192269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
    Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
    Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoreactive prostate-specific acid phosphatase in prostatic cancer.
    Kontturi M; Vihko P; Lukkarinen O; Vihko R
    Scand J Clin Lab Invest Suppl; 1985; 179():67-74. PubMed ID: 3866311
    [No Abstract]   [Full Text] [Related]  

  • 20. [Purification and determination of human prostate specific antigen in the serum].
    Ogawa Y; Morikawa J; Ohsawa R; Machida T; Miki M; Yanagisawa M
    Radioisotopes; 1984 May; 33(5):273-8. PubMed ID: 6206524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.